Skip to main content
. 2018 Apr 10;24:2134–2141. doi: 10.12659/MSM.906442

Figure 4.

Figure 4

Effect of PKC on expression and secretion of TGF-β1 and PDGF in HSCs. HSCs were treated with the solvent of drugs (Control), 3 μM phorbol 12-myristate 13-acetate (PMA, PKC agonist), and 1 μM calphostin C (PKC antagonist). ELISA results showing the secretion changes of TGF-β1 (A) and PDGF (B) in response to the solvent control (Control), PMA, and calphostin C. Representative blots showing TGF-β1 and PDGF expression levels in response to the solvent control (Control), PMA, and calphostin C (C). Reverse transcription PCR results showing mRNA changes in TGF-β1 (D) and PDGF (E) in response to the solvent control (Control), PMA, and calphostin C. Data are shown as the means ±SD. All differences were considered significant when * P<0.05 (n=7) compared with the solvent of drugs (Control).